Conceptus Intends to Offer $75 Million of Convertible Senior Notes.
In connection with the offering of the notes, the Company also expects to enter into convertible note hedge transactions with certain dealers. The convertible note hedge transactions are expected to reduce the potential dilution upon conversion of the notes. The Company intends to use a portion of the net proceeds from the offering of the notes together with the proceeds from warrant transactions, which the Company also intends to enter into with certain dealers, to fund the cost of the convertible note hedge transactions. If the underwriter exercises its over-allotment option, the Company intends to use a portion of the net proceeds from the sale of the additional notes, together with proceeds from additional warrant transactions, to enter into additional convertible note hedge transactions.
In connection with the convertible note hedge transactions, it is expected that the dealers that are party to such transactions, or their affiliates, will enter into various derivative or other transactions with respect to Conceptus common stock. In addition, following pricing of the offering of the notes, such parties or their affiliates may continue to enter into, or to unwind, various derivatives transactions with respect to Conceptus common stock and/or to purchase or sell shares of Conceptus common stock in secondary market transactions, including during the cash settlement averaging period relating to a conversion of the notes.
The Company intends to use the remaining net proceeds from this offering for general corporate purposes, which may include working capital and/or possible acquisitions of other businesses, technologies or products.
UBS Investment Bank is acting as sole book-running manager in connection with the offering.
The public offering of the Company's convertible senior notes will be made only by means of a prospectus and prospectus supplement under the Company's existing $150 million shelf registration statement. The prospectus and a preliminary prospectus supplement relating to the offering have been filed with the Securities and Exchange Commission and are available on the SEC's website at www.sec.gov. Copies of the prospectus and preliminary prospectus supplement may also be obtained from UBS Investment Bank, Attention: Prospectus Department, 299 Park Avenue, New York, New York, 10171, (888) 827-7275.
This press release does not constitute an offer to sell or solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Conceptus, Inc. manufactures and markets the Essure Permanent Birth Control system, an innovative medical device and procedure designed to provide a non-incisional alternative to tubal ligation, which is currently the leading form of birth control worldwide. Additional information about the Essure procedure is available at www.essure.com or by calling the Essure Information Center at 1-877-ESSURE1. Additional information about Conceptus is available at www.conceptus.com or by calling 1-877-ESSURE2.
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 5, 2007|
|Previous Article:||Fitch Upgrades Baton Rouge & EBR Parish, LA Sales Tax Bonds to 'AA'.|
|Next Article:||ACE Limited Announces Pricing of $500 Million Senior Note Offering by Subsidiary.|